PharmaEngine, Inc.

Taipei Exchange 4162.TWO

PharmaEngine, Inc. Free Cash Flow Yield on January 14, 2025: 2.05%

PharmaEngine, Inc. Free Cash Flow Yield is 2.05% on January 14, 2025, a 17.14% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

PharmaEngine, Inc. 52-week high Free Cash Flow Yield is 2.37% on August 06, 2024, which is 15.51% above the current Free Cash Flow Yield.
PharmaEngine, Inc. 52-week low Free Cash Flow Yield is 1.66% on February 15, 2024, which is -19.12% below the current Free Cash Flow Yield.
PharmaEngine, Inc. average Free Cash Flow Yield for the last 52 weeks is 2.00%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Taipei Exchange: 4162.TWO

PharmaEngine, Inc.

CEO	Mr. Hong-Ren Wang Ph.D.
IPO Date	June 20, 2012
Location	Taiwan
Headquarters	10 Minsheng East Road
Employees	17
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It is developing ONIVYDE, a proprietary liposome encapsulation of irinotecan, a topoisomerase 1 inhibitor for the treatment of metastatic pancreatic cancer; PEP06, which is in Phase I clinical trial for the treatment of cancer; and PEP07, a Chk1 inhibitor, which is in preclinical development stage to accumulate DNA damage in cells, lead to replication catastrophe, and induce cell apoptosis. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

Key trends

Past 5 years